Polymorphic Sodium Salt Forms for CCR9 Antagonist Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a stable, crystalline form of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide suitable for oral administration to effectively antagonize the CCR9 receptor and treat CCR9-mediated disorders such as inflammatory bowel disease.
Innovation Solution
Development of novel polymorphic solvated and desolvated forms of the sodium salt, characterized by specific X-ray powder diffraction patterns, Raman spectra, and thermal analysis profiles, including forms with solvents like 1,4-dioxane/water, formamide, dimethylsulfoxide, and the desolvated crystalline form, which are suitable for oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If an amorphous form of the pharmaceutical compound is developed, then ease of manufacture is improved, but stability and crystallinity are worsened
Solution Approach 1:
The patent applies parameter changes by transforming the physical state of the compound from amorphous to crystalline through controlled crystallization processes. Specific parameters such as temperature, solvent composition, and cooling rates are adjusted to induce and control crystal formation, thereby improving stability while maintaining manufacturability through defined crystallization protocols
2Stability of the object's composition
If a highly crystalline form of the compound is developed, then stability is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs preliminary action by pre-defining specific crystallization conditions and protocols before actual manufacturing. Standardized procedures for solvent selection, temperature profiles, and crystallization kinetics are established in advance, allowing complex crystalline forms to be produced through routine, well-controlled processes rather than ad-hoc methods
Solution Approach 2:
The patent utilizes phase transitions by controlling the transformation from liquid or amorphous phases to crystalline phases through carefully managed conditions. By understanding and controlling these phase transitions, the patent achieves highly crystalline forms through systematic manipulation of temperature, pressure, and solvent conditions, reducing manufacturing complexity
3Reliability
If a stable crystalline form suitable for oral administration is developed, then reliability is improved, but the complexity of characterizing and measuring specific polymorphic forms increases
Solution Approach 1:
The patent applies color changes as a characterization tool by utilizing differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) where thermal transitions and weight changes produce detectable signals. These methods provide reliable, easily measurable indicators of crystalline form and stability without requiring complex analytical equipment
Solution Approach 2:
The patent replaces complex mechanical or structural characterization methods with thermal analysis techniques. Instead of using sophisticated X-ray diffraction or microscopy equipment, the patent employs DSC and TGA which use simple heating protocols and measure thermal responses, thereby reducing measurement complexity while maintaining reliability
Data Source
AI summary
Disclosed are novel polymorphic solvated and desolvated forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)phenyl]-benzenesulfonamide. One embodiment of the present invention is directed to a crystalline sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]benzenesulfonamide (hereinafter “Compound A-1,4-dioxane/water solvate”), wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles (°28), when measured using Cu Ku radiation, at about 4.0, 8.1, 10.1, 14.2, 16.2, 18.6, 20.3, 24.7, 25.0, and 26.5.